Bellerophon Therapeutics Inc. shares surged 20% in premarket trade, after the company reported positive results in a mid-stage trial of a treatment for pulmonary hypertension associated with chronic obstructive pulmonary disease. The company said the phase 2 trial of its INOpulse inhaled nitric oxide met its primary and secondary goals, showing statistically significant improvement in six-minute walking distance, hemodynamics and blood vessel volume. “COPD patients with associated pulmonary hypertension have a poor prognosis with an approximately 4-year life expectancy and high hospitalization rates, which represents a significant unmet medical need for a safe and effective long-term treatment,” said Dr. Raymond L. Benza of the Cardiovascular Institute at Allegheny General Hospital, Pittsburgh, PA and Chairman of Bellerophon’s PH-COPD steering committee. The company is planning to conduct a larger phase 2b study of the treatment. Shares have gained 117% in 2017, while the S&P 500 has gained 10.6%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News